Trial Design & Conduct Apps
Contact
- Biostatistics Education irvinginst_berd_edu@cumc.columbia.edu
The trial and conduct apps allow users to upload a dataset and assign the next dose or determine the maximum tolerated dose. The apps contain descriptions of the required data as well as sample datasets.
CRM Conduct
- Assign next dose and estimate MTD using CRM
The Continual Reassessment Method (CRM) is a model-based design for phase I trials which aims to find the maximum tolerated dose of a new therapy.
PRO-CRM Conduct
- Assign next dose and estimate MTD using PRO-CRM
Patient-Reported Outcomes Continual Reassessment Method (PRO-CRM) incorporates both clinician and patient perspective to estimate the maximum tolerated dose.
TiTE-CRM Conduct
- Assign next dose and estimate MTD using TiTE-CRM
Time-to-Event Continual Reassessment Method (TiTE-CRM) accounts for the timing of late-onset toxicities and results in shorter trial duration.
Icons created by Emma Lafaurie
Cite it, Submit it, Share it!
If your research has benefited from one or more Irving Institute resources, please remember to:
- Cite our CTSA grant in any relevant publications, abstracts, chapters, and/or posters.
- Submit your publications to PubMed Central (PMC) for compliance with the NIH Public Access Policy.
- Share your research updates with us by sending an email to: irving_institute@cumc.columbia.edu